» Articles » PMID: 7643951

Epidemiology of Creutzfeldt-Jakob Disease in the United States, 1979-1990: Analysis of National Mortality Data

Overview
Specialties Neurology
Public Health
Date 1995 Jan 1
PMID 7643951
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The trends and current incidence of Creutzfeldt-Jakob disease (CJD) was examined by using a unique and potentially high sensitive source for case ascertainment. We analyzed death certificate information for 1979-1990 from US multiple-cause-of-death mortality data, compiled by the National Center for Health Statistics, Centers for Disease Control and Prevention. We evaluated death certificate data for US residents for whom CJD was listed as one of the multiple causes of death on the death certificate (046.1) from the International Statistical Classification of Diseases, Injuries, and Causes of Death (9th revision). Age-adjusted and age-specific CJD death rates by gender, race, and region were calculated to measure the disease incidence because of the rapidly fatal course of the disease for most patients with CJD. We identified 2,614 deaths with CJD listed on the death certificates. The average annual age-adjusted mortality rate was 0.9 deaths per million persons (range 0.8-1.1). The mean age at death was 67 years. CJD-related deaths were uncommon among persons younger than 50 years of age (4.3% of all deaths). The highest average annual mortality rate was for those persons aged 70-74 years (5.9 deaths per million persons). A slight majority (53.0%) of the deaths was in females, but the age-adjusted mortality rate was 1.2 times higher for males. Most deaths (94.8%) were in whites; the mortality rate for blacks was only 40% of that for whites. The age-adjusted CJD mortality rate in the United States is similar to published estimates of the crude incidence of CJD worldwide.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Human prion diseases in the United States.

Holman R, Belay E, Christensen K, Maddox R, Minino A, Folkema A PLoS One. 2010; 5(1):e8521.

PMID: 20049325 PMC: 2797136. DOI: 10.1371/journal.pone.0008521.


Creutzfeldt-Jakob disease mortality in Japan, 1979-2004: analysis of national death certificate data.

Doi Y, Yokoyama T, Sakai M, Nakamura Y J Epidemiol. 2007; 17(4):133-9.

PMID: 17641449 PMC: 7058474. DOI: 10.2188/jea.17.133.


Detection and localization of PrPSc in the skeletal muscle of patients with variant, iatrogenic, and sporadic forms of Creutzfeldt-Jakob disease.

Peden A, Ritchie D, Head M, Ironside J Am J Pathol. 2006; 168(3):927-35.

PMID: 16507908 PMC: 1606529. DOI: 10.2353/ajpath.2006.050788.


Ensuring the biologic safety of plasma-derived therapeutic proteins: detection, inactivation, and removal of pathogens.

Cai K, Gierman T, Hotta J, Stenland C, Lee D, Pifat D BioDrugs. 2005; 19(2):79-96.

PMID: 15807628 PMC: 7099715. DOI: 10.2165/00063030-200519020-00002.


Creutzfeldt-Jakob disease in Sweden.

Lundberg P J Neurol Neurosurg Psychiatry. 1998; 65(6):836-41.

PMID: 9854958 PMC: 2170389. DOI: 10.1136/jnnp.65.6.836.